Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0162
NEWS & VIEWS
|
Cetuximab limitations and renew interest in surgical resection and research advances for improving stage IV colorectal cancer outcome.
|
Dimosthenis Ziogas , M.D.
|
Affiliation: Dimosthenis Ziogas M.D., Dept of Surgery, University of Ioannina, School of Medicine, 45110 Ioannina, Greece .
E-mail: deziogas@hotmail.com |
Since there is no abstract available we provide the first paragraph.
The advent of targeted therapy with the approval of cetuximab or panitumumab has created excitement for the improvement of survival of patients with stage IV colorectal cancer. However, a more recent phase 3 randomized trial found no overall survival benefit either in the whole population of in the KRAS wild-type metastatic colorectal cancer [1]. The question therefore whether surgery in stage IV of colorectal cancer gains again new interest for improving the outcomes of these patients remains [2].
(Citation: Gastric & Breast Cancer 2011; 10(2): 94-96)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
